O'HANDNCT04035005
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 47 versions: 43 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 39 words Show 4 more changesShow less
- Study completion pushed from Jan 19, 2028 to Apr 15, 2028
- Study sites: 155 to 153
- Secondary endpoints: details revised at 10 of 13 entries
- Publications: details revised at 1 of 1 entry
- Notable Results first posted: Feb 23, 2026
- Secondary endpoints: details revised at 4 of 13 entries
- Study sites revised (155)
- Notable Primary endpoints: 1 to 2
- Study sites: 159 to 155
- Secondary endpoints: 12 to 13
Notable Eligibility criteria expanded, about 6 wordsv44 Show 5 more changesShow less
- Primary endpoint revised
- Enrollment target: estimated 1000 to confirmed 1013
- Study sites: 161 to 159
- Secondary endpoints: 9 to 12
- Study description shortened, about 48 words
- Minor Study sites: 160 to 161v43
Show 37 earlier versionsHide 37 earlier versions
- Minor Site details revised at 3 of 160 sitesv42
- Minor Study sites: 158 to 160v41
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 209 to 158
- Minor Study sites revised (209)v38
- Minor Study sites revised (209)v37
- Notable Primary completion date: Dec 10, 2027 to Jan 15, 2025
- Study completion date: Nov 11, 2030 to Jan 19, 2028
- Study sites revised (209)
- Minor Site details revised at 2 of 209 sitesv35
- Minor Site details revised at 1 of 209 sitesv34
- Minor Site details revised at 1 of 209 sitesv33
- Minor Site details revised at 4 of 209 sitesv32
- Minor Site details revised at 1 of 209 sitesv31
- Minor Site details revised at 3 of 209 sitesv30
- Minor Site details revised at 2 of 209 sitesv29
- Minor Study sites revised (209)v28
- Minor Site details revised at 3 of 209 sitesv27
- Minor Site details revised at 1 of 209 sitesv25
- Minor Study sites: 208 to 209v24
- Notable Primary completion date: Aug 20, 2026 to Dec 10, 2027
- Study sites: 207 to 208
- Study completion date: Apr 4, 2028 to Nov 11, 2030
- Minor Study sites: 205 to 207v22
- Minor Site details revised at 1 of 205 sitesv21
- Minor Study sites: 203 to 205v20
- Minor Study sites: 202 to 203v19
- Minor Study sites: 201 to 202v18
- Notable Primary completion date: Apr 1, 2025 to Aug 20, 2026
- Study sites: 198 to 201
- Minor Study sites: 208 to 198v15
- Notable Eligibility criteria revised
- Study sites: 238 to 208
- Minor Site details revised at 5 of 238 sitesv12
- Minor Study sites: 239 to 238v11
- Minor Study sites revised (239)v10
- Minor Study sites: 240 to 239v9
- Notable Eligibility criteria expanded, about 29 words
- Study sites: 244 to 240
- Secondary endpoints revised (9)
- Notable Eligibility criteria expanded, about 32 words
- Study sites: 242 to 244
- Minor Site details revised at 31 of 242 sitesv6
- Minor Study sites: 241 to 242v5
- Minor Study sites: 238 to 241v4
- Minor Study sites: 235 to 238
- Study completion date: Jul 1, 2028 to Apr 4, 2028
- Start date changed from estimate of Sep 1, 2019 to Aug 12, 2019
- Minor Study sites: 233 to 235v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12) in FAS
Timeframe: Up to approximately 243 weeks
Time to Onset of cCDP12 in Magnetic Resonance Imaging (MRI) Activity Analysis Set
Timeframe: Up to approximately 243 weeks
Secondary (13)
Time to 12-week CDP in 9-HPT
Time to 12-week CDP in EDSS
Time to 24-week CDP in 9-HPT
Time to 24-week CDP in EDSS
Annual Rate of Change From Baseline in Radius of Total Volume of T2 Lesions
Show 8 moreShow less
Annual Rate of Percent Change From Week 24 in Total Brain Volume
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Serum Concentration of Ocrelizumab
B-cell Levels in Blood
Change From Baseline in B-cell Levels
Percentage of Participants With B-cell Counts ≤5 Cells/μL
Percentage of Participants With B-cell Counts ≤10 Cells/μL
Number of Participants With ADAs to Ocrelizumab
Arms and interventions
OcrelizumabExperimental
Participants will receive ocrelizumab by intravenous (IV) infusion every 24 weeks.
PlaceboPlacebo comparator
Participants will receive placebo matched to ocrelizumab by IV infusion every 24 weeks.
Drugs: Ocrelizumab, Placebo
Sites
153 sites in 23 countries
Ukraine 21, Poland 20, Russia 20, Spain 10, United Kingdom 9, United States 8, Italy 7, Serbia 7, France 6, Mexico 5, Portugal 5, Canada 4, Romania 4, Tunisia 4, Australia 3, Belgium 3, Bulgaria 3, Croatia 3, Georgia 3, Colombia 2, Lebanon 2, Morocco 2, New Zealand 2